More specifically, preliminary clinical trial results of CD19/CD22 CAR-T cell therapy have demonstrated promising efficacy in adult patients with ALL and diffuse large B cell lymphoma50,51. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.